

Regional Drugs Testing Laboratory Directorate General of Health Services, Guwahati (India) - 781022 Fax: 0361-2338555/2330555 Phone No.0361 2338555

Email:rdtlguwahati@cdsco.nic.in

FORM 13 (See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940.

1. Name of Inspector from whom received

Office of the Chief Medical Officer

Kolasib, Mizoram- 796082

2. Serial No. and date of Inspector's memorandum

: KLB/11/2025/IPA/DRUGS, 03-FEB-2025

al Drugs

3. Number of Sample

: NIL

4. Date of receipt

: 13-FEB-2025

5. Names of drugs purporting to be contained in the sample : Azithromycin Tablets I.P. (ZAX 250)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2024- 25/1943	GUW/LS/2025- 26/41	TI-23090	Sep-2023 Aug-2025	TROL NARCE	Horizon Bioceuticals Pvt. Ltd, Plot No. 3A, Ind. Area, Trilokpur Road, Kala Amb, Distt, Sirmour (H.P.).
,					ž.

6. Condition of seals on

[the packet or on portion of sample or container]

Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing: From 27-Feb-2025 To 27-Mar-2025

COMPOSITION

Each film coated tablet contains: Azithromycin IP eq. to Anhydrous

Azithromycin 250 mg.

Protocol Applied: I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, oval shaped, bi-convex, scored on one surface, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Azithromycin.	NA
3	Average weight	0.3644 g	NA
4	Uniformity of weight	Complies.	NA
5	Dissolution	Complies.	NLT 75 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
	a L	· 4			14	, x

1	Azithromycin Eq. to Anhydrous Azithromycin	241.8 mg/Tablet	250 mg/Tablet	96.72	90 % to 110 %	I.P. 2022
In the oni	nion of the undersians	1.0			ر و الملاق ال	

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 07-APR-2025

GOVERNMENT ANALYST

Rinku Kalita Government Analyst R.D.T.L., Guwahati-22

GS STANDARD CONTROL

-- END OF REPORT --